Export

Beyond the biggest drug maker others are topping the tables in 2018

Date June 20, 2012

Predicting the world’s biggest sellers of drugs in years to come is only one way to paint a picture of the future of the pharmaceutical industry. Novartis currently holds that title, while on other measures the ranking tables look very different.

For example, Roche is seen remaining the most substantial presence in the biotechnology world until 2018 by a considerable margin, a result of a huge monoclonal antibody franchise that also sees it dominate in oncology, EvaluatePharma data reveal. Novo Nordisk is unsurprisingly forecast to continue its domination of the anti-diabetic space although Merck & Co is set to take the second spot thanks to the success of the DPP-IV inhibitor Januvia, which on current estimates is set to become the world’s top-selling medicine in 2018 (see tables below).

WW Prescription Drug Sales: Top 5 Companies 
         WW Prescription Sales ($bn)   
Rank  Company  2011  2018  % CAGR 11-18 
Novartis  46.7  51.3  1% 
Pfizer  53.5  48.2  (1%) 
Sanofi  39.3  48.2  3% 
GlaxoSmithKline  34.9  44.9  4% 
Roche  37.0  43.9  2% 

The table above - constructed by EvaluatePharma from equity analysts’ forecasts and available in the World Preview 2018- shows that Novartis is emerging as a clear leader in terms of prescription drug sales in 2018. Behind it Sanofi and Pfizer are neck and neck; a couple of pipeline hits or misses and this league table could easily shift in the coming years.

Novartis’ growth is coming in large part from its expanding generics drug portfolio, via Sandoz, while Sanofi has been elevated by the addition of the Genzyme products it bought last year.

Roche, meanwhile, is seen benefiting largely from growth in new and existing franchises, most notably the breast cancer drugs Perjeta or pertuzumab, which recently won approval in the US, and the antibody drug conjugate trastuzumab-DM1, which should reach the market next year. Both of these biotechnology products and growing demand for Avastin and Actemra will also help keep Roche at the top of the biotech league table, the table below shows.

WW Prescription Drug Sales from Biotechnology in 2018: Top 10 Companies 
    WW Sales ($bn)   
Rank  Company  2011  2018  % CAGR 11-18 
Roche  25.7  32.6  3% 
Novo Nordisk  11.4  19.6  8% 
Sanofi  11.5  17.8  6% 
Pfizer  10.1  14.3  5% 
Amgen  14.4  13.6  (1%) 
GlaxoSmithKline  4.7  12.5  15% 
Johnson & Johnson  6.8  8.5  3% 
Merck & Co  7.7  8.4  1% 
Eli Lilly  5.3  8.3  7% 
10  Abbott Laboratories  8.1  7.6  (1%) 

As the World Preview report reveals elsewhere, biotechnology products (bioengineered vaccines and biologics) will account for 49% of world's top 100 drugs in 2018, up from 34% in 2011. At the same time, the total value of biotechnology sales is set to grow 51% between 2011 and 2018, from $142bn to $215bn.

Roche is set to remain unrivalled king of that castle, with biotech sales reaching $32.6bn by then; Novo’s insulin franchise makes it number two, while thanks to the Genzyme acquisition Sanofi has kept pace.

Amgen, often described as the world’s biggest biotech, risks falling out of the top five, with Glaxo just behind it . Impressive 15% annual growth to 2018 is forecast for the UK drug maker in this category, with success in vaccines and antibodies like Benlysta and Arzerra adding to its biotech sales.

Therapy dominance

As revealed yesterday Roche is also set to continue its domination of the oncology space out to 2018, the largest and one of the fastest growing therapies (Roche adds to pipeline with side bet on CNS, June 19, 2012).

Behind oncology, in terms of projected value in 2018, are diabetes medicines, driven by the surging prevalence of the type II variety across the globe. This therapy area is seen almost doubling in value by 2018 to be worth $58.2bn with many classes of drug contributing to that growth: modern insulins, DPP-IV inhibitors and GLP-1 agonists.

The table below shows that Novo is seen extending its dominance, thanks to growth in its existing insulin franchise and a new addition, degludec, as well as growing demand for the GLP-1 agonist Victoza.

Merck's second place is due largely to the DPP-IV inhibitor Januvia, which as the table at the end of the article reveals is forecast to be the biggest-selling drug in 2018. Consensus forecasts for the product have been creeping up gradually over the past couple of years.

Top 5 Companies & Total WW Anti-Diabetic Sales 2011-18 
    WW Sales ($m)   
Rank  Company  2011  2018  % CAGR 11-18  
Novo Nordisk  9,420  16,733  9% 
Merck & Co  4,727  9,586  11% 
Sanofi  6,506  8,007  3% 
Eli Lilly  3,784  5,320  5% 
Takeda  4,405  4,059  (1%) 

Anti-rheumatics, meanwhile, are seen as the third most-valuable therapy area in 2018, worth $45bn, up from $38bn last year.

Interestingly, none of the top companies in this therapy area are seen registering impressive growth rates over the next few years. Abbott, which tops the table thanks to Humira, is not expected to wring much more growth out of the product in years to come, held back by fierce competition in the anti-TNF class and the entrance of oral agents.

The first, Pfizer's tofacitinib, should be approved later this year.

Top 5 Companies & Total WW Anti-rheumatic Sales 2011-18 
    WW Sales ($m)   
Rank  Company  2011  2018  % CAGR 11-18 
Abbott Laboratories  7,932  7,281  (1%) 
Pfizer  7,365  6,875  (1%) 
Johnson & Johnson  4,280  5,372  3% 
Amgen  3,701  3,103  (2%) 
Merck & Co  3,362  2,799  (3%) 

Finally, on current estimates analysts reckon Januvia will become the biggest-selling drug in 2018, easily robbing Humira of that crown. With a new swathe of GLP-1 agonists approaching the market, which many believe will overcome the tolerability and safety issues that held back the first entrants, it remains to be seen whether Januvia can hit these estimates.

2018: Top 10 Selling Products WW 
        WW Product Sales ($m)   
Rank  Product  Company  Pharmacological Class  2011  2018  % CAGR 11-18 
Januvia/Janumet  Merck + Ono + Almirall  DPP-IV inhibitor  5,096  9,705  10% 
Humira  Abbott + Eisai  Anti-TNFa MAb  8,236  8,167  (0%) 
Avastin  Roche  Anti-VEGF MAb  5,984  7,576  3% 
Enbrel  Amgen + Pfizer + Takeda  TNFa inhibitor  7,892  7,187  (1%) 
Revlimid  Celgene  Immunomodulator  3,208  6,751  11% 
Prevnar 13  Pfizer  Pneumococcal vaccine  3,657  6,720  9% 
Rituxan  Roche + Biogen Idec  Anti-CD20 MAb  6,790  6,335  (1%) 
Lantus  Sanofi  Insulin  5,451  5,989  1% 
Remicade  J&J + Merck + Mitsubishi Tanabe  Anti-TNFa MAb  7,187  5,841  (3%) 
10  Seretide/Advair  GSK + Almirall + Faes  Beta 2 adrenoreceptor agonist & corticosteroid  8,233  5,734  (5%) 

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2017 EP Vantage Ltd